15/12/2005 - Latest data by La Jolla Pharmaceuticals indicate the potential of novel, orally active small molecule inhibitors of a central enzyme may provide clinical benefit for the treatment of stroke, ulcerative colitis, and other autoimmune diseases and inflammatory disorders.